poisar

Stock

X4 Pharmaceuticals, Inc. XFOR

$4.23+1.32%

Overview

XFOR market data

Price History

XFOR price chart · 1M
O
4.15
H
4.39
L
4.15
C
4.23
Vol
40,389.00
Source
US equities market feed
Observed
Aug 27, 2026, 12:00 AM
Cadence
Five-minute page cache; daily and stored hourly bars
Status
fresh

Key Stats & Performance

Open
$4.15
Previous Close
$4.17
Day High
$4.39
Day Low
$4.15
52 Week High
$4.82
52 Week Low
$3.56
7 Day Return
+4.84%
30 Day Return
+7.51%
90 Day Return
-1.86%
1 Year Return
+3.05%
Daily Notional Volume
$170.6K
Latest daily bar volume multiplied by its closing price.

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$1.87
Diluted earnings per share over the trailing twelve months.
Beta
0.43
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
-1,106.3%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$2.80 – $4.83
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $404.6M · P/B 1.96 · P/S 44.89.

Company News

7 captured
FDA Provides Orphan Drug Designation To X4 Pharmaceuticals' Mavorixafor To Treat CongenitalBenzinga · Aug 26, 2026, 4:54 PM
Airsculpt Technologies, Barrick Mining And Other Big Stocks Moving Lower In Monday’s Pre-Market SessionBenzinga · Aug 10, 2026, 12:02 PM
X4 Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results.Benzinga · Aug 7, 2026, 4:04 PM
X4 Pharmaceuticals Q2 EPS $(0.13) Beats $(0.18) Estimate, Sales $8.806M Beat $2.420M EstimateBenzinga · Aug 6, 2026, 9:22 PM
Wells Fargo Initiates Coverage On X4 Pharmaceuticals with Overweight Rating, Announces Price Target of $11Benzinga · Jul 10, 2026, 12:25 PM
8-K filing — X4 Pharmaceuticals, Inc (XFOR)SEC EDGAR · Jul 1, 2026, 8:13 PM
Leerink Partners Initiates Coverage On X4 Pharmaceuticals with Outperform Rating, Announces Price Target of $12Benzinga · Jun 2, 2026, 1:20 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock